Capecitabine-induced cardiotoxicity: case report and review of the literature

Current Oncology

Volumn 17, Issue 1, 2010, Pages 59-63

  Ang, C ^a   Kornbluth, M ^a   Thirlwell, M P ^a   Rajan, R D ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

5 Fluorouracil; Capecitabine; Cardiotoxicity; Chemotherapy

Indexed keywords

CAPECITABINE; DALTEPARIN; FLUOROURACIL; FOLINIC ACID; METFORMIN; OXALIPLATIN; SOTALOL; VALSARTAN; VENLAFAXINE;

AGED; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; CARDIOGENIC SHOCK; CARDIOTOXICITY; CASE REPORT; COLON ADENOCARCINOMA; COLON CANCER; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FLUSHING; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIA; MALE; MONOTHERAPY; PACEMAKER; SIDE EFFECT; SINUS ARREST; SINUS BRADYCARDIA; SYNCOPE; TREATMENT OUTCOME;

EID: 75849121628     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i1.437     Document Type: Article

References (31)

1. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 1993;71:493-509.
2. Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58:487-93.
3. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993;50:441-4.
4. Wacker A, Lersch C, Scherpinski U, Reindl L, Seyfarth M. High incidence of angina pectoris in patients treated with 5-flurouracil. A planned surveillance study with 102 patients. Oncology 2003;65:108-12.
5. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134: 75-82.
6. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
7. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13:484-5.
8. Wijesinghe N, Thompson PI, McAlister H. Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006;15:337-9.
9. Goldsmith YB, Roitacher N, Baum MS. Capecitabine-induced coronary vasospasm. J Clin Oncol 2008;17:3802-4.
10. Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990;29:1001-3.
11. Freeman NJ, Constanza ME. 5-Fluorouracil cardiotoxicity. Cancer 1998;61:36-45.
12. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006;25:305-9.
13. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. Cancer 1988;62:266-9.
14. Patel B, Kloner RA, Ensley J, Al-Sarraf M, Kish J, Wynne J. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-43.
15. Lemaire L, Malet-Martino MC, de Forni M, Martino R, Lasserre B. Cardiotoxicity of 5-fluorouracil vials stems from alkaline hydrolysis of this drug. Br J Cancer 1992;66:119-27.
16. Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines IX-the degradation of 5-fluorouracil. J Biol Chem 1960;235:433-7.
17. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jap J Pharmacol 1980;30:871-9.
18. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10:1795-801.
19. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65:885-9.
20. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006;4:1-5.
21. Ciccolini J, Mercier C, Dahan L, et al. Toxic death-case after capecitabine-oxaliplatin (XELOX) administration: probable implication of dihydropyridine dehydrogenase deficiency. Cancer Chemother Pharmacol 2006;58:272-5.
22. Mercier C, Dupuis C, Blesius A, et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother Pharmacol 2009;63:1177-80.
23. Haller DG, Cassidy J, Clark SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118-23.
24. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori 1982;68:505-10.
25. Ng M, Cunninham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005;41:1542-6.
26. Tsibiribi P, Descotes J, Lombard-Bohas C, et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006;93:E27-30.
27. Galderisi M, Marra F, Esposito R, Lomoriello VS, Pardo M, de Divitiis O. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007;5:4.
28. Holubec L Jr, Topolcan O, Finek J, et al. Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients-a pilot study. Anticancer Res 2007;27:1883-6.
29. Cianci G, Morelli MF, Cannita K, et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br J Cancer 2003;88:1507-9.
30. Talapatra K, Rajesh I, Rajesh B, Selvamani B, Subhashini J. Transient asymptomatic bradycardia in patients on infusional 5-fluorouracil. J Cancer Res Ther 2007;3:169-71.
31. Shoemaker LK, Arora U, Rocha Lima CM. 5FU-induced coronary vasospasm. Cancer Control 2004;11:46-9.